Janssen submits extended MAA for paliperidone palmitate to EMA for schizophrenia treatment
Paliperidone palmitate once-monthly is an atypical long-acting injection to treat schizophrenia and is now approved in more than 80 countries, while the drug is marketed as Xeplion in